See more : Dongwon Industries Co., Ltd. (006040.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Isofol Medical AB (publ) (ISOFOL.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Isofol Medical AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- Panasonic Manufacturing Malaysia Berhad (3719.KL) Income Statement Analysis – Financial Results
- Playgon Games Inc. (PLGNF) Income Statement Analysis – Financial Results
- Heliostar Metals Ltd. (HSTXF) Income Statement Analysis – Financial Results
- ibis inc. (9343.T) Income Statement Analysis – Financial Results
- Foxby Corp. (FXBY) Income Statement Analysis – Financial Results
Isofol Medical AB (publ) (ISOFOL.ST)
About Isofol Medical AB (publ)
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 721.00K | 12.80M | 22.41M | 37.12M | 0.00 | 0.00 | 227.00K | 508.00K | 187.00K | 0.00 |
| Cost of Revenue | 35.14M | 178.50M | 226.03M | 199.54M | 1.55M | 157.00K | 157.00K | 132.00K | 110.40K | 0.00 |
| Gross Profit | -34.42M | -165.71M | -203.62M | -162.42M | -1.55M | -157.00K | 70.00K | 376.00K | 76.61K | 0.00 |
| Gross Profit Ratio | -4,773.23% | -1,294.89% | -908.74% | -437.55% | 0.00% | 0.00% | 30.84% | 74.02% | 40.97% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 196.71M | 199.54M | 137.82M | 72.12M | 61.21M | 57.08M | 34.90M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.27M | 34.75M | 196.71M | 199.54M | 137.82M | 72.12M | 61.21M | 57.08M | 34.90M | 12.48M |
| Other Expenses | 0.00 | 180.26M | 30.16M | 24.08M | 29.99M | 17.73M | 11.38M | 6.93M | 5.79M | 0.00 |
| Operating Expenses | 7.27M | 180.26M | 226.87M | 223.61M | 167.80M | 89.85M | 72.59M | 64.02M | 40.69M | 10.53M |
| Cost & Expenses | 42.40M | 180.26M | 226.87M | 223.61M | 167.80M | 89.85M | 72.59M | 64.02M | 40.69M | 10.53M |
| Interest Income | 4.57M | 147.00K | 5.00K | 4.00K | 8.00K | 0.00 | 558.00K | 1.00K | 0.00 | 70.98K |
| Interest Expense | 0.00 | 44.00K | 168.00K | 153.00K | 183.00K | 638.00K | 6.00K | 2.00K | 1.00K | 0.00 |
| Depreciation & Amortization | 37.00K | 67.00K | 1.60M | 1.77M | 1.55M | 157.00K | 157.00K | 132.00K | 110.00K | 107.72K |
| EBITDA | -37.02M | -159.73M | -198.49M | -187.07M | -163.15M | -89.69M | -71.88M | -64.82M | -40.58M | -10.42M |
| EBITDA Ratio | -5,135.09% | -1,264.99% | -901.60% | -498.54% | 0.00% | 0.00% | -31,661.67% | -12,575.59% | -21,699.47% | 0.00% |
| Operating Income | -41.68M | -167.46M | -204.47M | -186.49M | -167.80M | -89.85M | -72.59M | -64.02M | -40.69M | -10.53M |
| Operating Income Ratio | -5,781.28% | -1,308.59% | -912.51% | -502.42% | 0.00% | 0.00% | -31,976.65% | -12,601.77% | -21,758.29% | 0.00% |
| Total Other Income/Expenses | 4.61M | 7.75M | 4.21M | -2.50M | 6.22M | 6.72M | 552.00K | -2.00K | -1.00K | -70.98K |
| Income Before Tax | -37.07M | -159.76M | -200.25M | -188.99M | -161.58M | -83.13M | -72.04M | -64.02M | -40.69M | -10.60M |
| Income Before Tax Ratio | -5,141.61% | -1,248.38% | -893.70% | -509.15% | 0.00% | 0.00% | -31,733.48% | -12,601.97% | -21,758.82% | 0.00% |
| Income Tax Expense | 0.00 | -3.81M | -3.37M | 1.00K | -4.35M | 7.36M | 558.00K | 1.00K | 0.00 | 0.00 |
| Net Income | -37.07M | -155.94M | -196.88M | -188.99M | -157.23M | -83.13M | -72.04M | -64.02M | -40.69M | -10.60M |
| Net Income Ratio | -5,141.61% | -1,218.59% | -878.67% | -509.15% | 0.00% | 0.00% | -31,733.48% | -12,601.97% | -21,758.82% | 0.00% |
| EPS | -0.23 | -0.97 | -1.57 | -2.43 | -2.79 | -1.48 | -1.48 | -2.26 | -1.38 | -1.53 |
| EPS Diluted | -0.23 | -0.97 | -1.57 | -2.43 | -2.79 | -1.48 | -1.47 | -2.26 | -1.38 | -1.53 |
| Weighted Avg Shares Out | 161.52M | 161.52M | 125.65M | 77.76M | 56.44M | 56.35M | 48.78M | 28.34M | 29.41M | 6.95M |
| Weighted Avg Shares Out (Dil) | 161.52M | 161.52M | 125.65M | 77.76M | 56.44M | 56.35M | 48.85M | 28.34M | 29.41M | 6.95M |
Source: https://incomestatements.info
Category: Stock Reports